Association between village coverage of 13-valent pneumococcal conjugate vaccine and vaccine-type pneumococcal carriage among children aged 0–59 months with pneumonia in Papua New Guinea: an observational study

Read full text Summarise with VIRAT
Authors: Rebecca L. Ford, Eleanor Frances Georgina Neal, Joycelyn Sapura, John Kave, Birunu Nivio, Mary Dreyam, John Samatoe, Wendy Kirarock, Jocelyn Chan, Jason Hinds, Monica Larissa Nation, Casey L. Pell
+8 more Belinda Daniela Ortika, Ahmed Alamrousi, Cattram D. Nguyen, Eileen Margaret Dunne, Catherine Satzke, William S. Pomat, Christopher C. Blyth, Fiona Mary Russell
Cited by: 0
References: 47

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background Pneumococcal conjugate vaccine (PCV) prevents pneumococcal disease and pneumonia, but indirect effects are poorly understood in low-coverage, high-burden settings like Papua New Guinea (PNG). PNG introduced 13-valent PCV (PCV13) in 2014. We aimed to assess direct and indirect effectiveness of PCV13 against vaccine-type pneumococcal carriage among children with pneumonia or suspected meningitis in PNG. Methods Children aged ≤59 months with pneumonia or suspected meningitis (cases) were enrolled at Eastern Highlands Provincial Hospital and nearby clinics (April 2016–December 2019). Clinical data, PCV13 status, and nasopharyngeal swabs were collected. Pneumococci were detected by lytA real-time PCR and serotyped by microarray. PCV13 coverage among village children ≤59 months was estimated via household surveys. Vaccine-type carriage by case-level PCV13 status was estimated. Associations between carriage and case PCV13 status (direct effects), and village-level coverage (indirect effects) were estimated using GEE logistic regression with village clustering. Results Among 1214 cases, vaccine-type carriage was lower in vaccinated (24.8%) than under-vaccinated (41.3%) cases. Adjusted PCV13 effectiveness against vaccine-type carriage was 46.6% (95% CI 27.0–60.9). Coverage surveys occurred in 148 villages (5978 children). Median village-level coverage increased from 2016 (12.5% [IQR 0–37.5]) to 2019 (28.6% [IQR 0–53.8]). Each percent increase in village coverage corresponded to a 0.5% (95% CI 0.0–1.0) decrease in vaccine-type carriage. Conclusions PCV13 vaccination reduced vaccine-type carriage in PNG. Despite low coverage, indirect effects were evident, consistent with emerging herd protection. These findings highlight the importance of strengthening PCV13 programs to optimise individual and community protection.

Fields of Study & Subjects

Pneumonia and Respiratory Infections Bacterial Infections and Vaccines Microbial infections and disease research

Publication details

Journal / source
Vaccine X
Volume
30
Pages
100811–100811
Publication date
27 March 2026
Language
EN